Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great $EMOR News today!
On the heels of Company’s recent acquisition of the 5 Star Pharmacy LLC, Healixa announces the Company’s new Rx brand for the digital pharmacy marketplace. The launch of the PurelyRx brand is a continuation of the Company’s extensive rebranding effort, focused on creating “healing” brands that are simplistic and memorable.
Healixa Inc. Announces its New Rx Brand Name, PurelyRx
Holbrook, New York, April 26, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, today announces the company’s newly developed brand, PurelyRx.
On the heels of Company’s recent acquisition of the 5 Star Pharmacy LLC, Healixa announces the Company’s new Rx brand for the digital pharmacy marketplace. The launch of the PurelyRx brand is a continuation of the Company’s extensive rebranding effort, focused on creating “healing” brands that are simplistic and memorable. “I have had the pleasure of being a part of many go-to-market initiatives,” commented Jessica Muzquiz, a recently appointed Advisory Board member of Healixa. “This one in particular is exciting, fresh, and full of creativity. The insight we’ve received from key demographics has been instrumental in developing this brand.”
Healixa continues to execute on its national pharmacy business plan rollout and deployment of the Company's Rx application, for which Healixa partnered to pilot with a globally recognized, tech-enabled last-mile logistics company. Retail pharmacy is a $500 billion industry that is currently reliant on expensive physical locations to drive foot traffic. Most central processing software systems in the market that manage prescriptions are outdated or unable to integrate their Application Programming Interface (“API”) to newly developed systems within the virtual care market. Healixa has turned these very challenges into opportunities by building a platform that gives all participants, including patients, doctors, pharmacists and payors, a modern digital user experience while simultaneously addressing backend platform flexibility and compatibility.
Healixa is well on its way and is laser-focused on creating satellite-fulfilment centers with advanced, proprietary technology, economies of scale, and same-day delivery. “The momentum and support from our internal team, the health care community, and globally recognized channel partners has been tremendous. Together, humanizing care becomes achievable," said Ian Parker CEO of Healixa Inc. “The PurelyRx brand will create lasting imprint on the ecosystem we are establishing.”
Healixa is scheduled to unveil PurelyRx’s new site and special features in the weeks to come. The Company is also planning on announcing newly accomplished milestones concurrent with this announcement.
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
$EMOR NEWS! CEO Presenting at the Emerging Growth Conference on April 28. Register Now https://finance.yahoo.com/news/ceo-presenting-emerging-growth-conference-110000810.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
"New To The Street" TV Announces Two Televised Broadcastings, One on Bloomberg Television, Today, Saturday, April 24, 2021 @ 6 Pm EDT, and a Second Broadcasting on Newsmax TV, Tomorrow, Sunday, April 25, 2021- Hour Slot 10-11am EDT
Emerald Organic Products Inc (EMOR)
1.20 -0.04
Global Cannabis Applications Corp (FUAPF)
0.1848 -0.00
Tonix Pharmaceuticals Holding Corp. (TNXP)
1.04 0.01
NEW YORK, April 24, 2021 (GLOBE NEWSWIRE) -- FMW Media’s “ New to The Street” TV broadcast its no. 170 show today on Bloomberg Television at 6 PM EST. And, broadcasting its 1- hour show tomorrow, April 25, 2021, on NEWSMAX TV from 10-11AM EST.
“New To The Street’s” TV shows features the following Companies and their businesses:
- Tonix Ph a rmaceuticals (NASDAQ: TNXP)
- Global Cannabis Applications Corp. (OTCPINK: FUAPF)
- Heali x a, Inc. (OTCPINK: EMOR)
- Finxflo Crypto (FXF)
- Petproducts.com
- Native Coin ( N8V )
Tonix Pharmaceuticals, Inc.’s (NASDAQ:TNXP) CEO, Seth Lederman, talks to “New To The Street” TV about their Company’s agreement with OyaGen, Inc. to license an experimental COVID-19 antiviral drug TNX-3500 (formerly known as OYA1) –Broadcast: Bloomberg TV and NEWSMAX TV.
Brad Moore, CEO at Global Cannabis Application Corp – “GCAC” (OTCPINK: FUAPF) talks on the show about their Company’s new definitive three-year software licensing agreement with Herb Industries Ltd. – Broadcast: Bloomberg TV and NEWSMAX TV.
“New To The Street” TV has CEO Ian Parker of Healixa, Inc. (OTCPINK:EMOR) who talks about the pilot roll-out in selected metro areas of the “last mile” digital pharmacy, a globally recognized tech enabled system . Mr. Parker also talks, on the show, about their “Justice League” of healthcare professionals, now formalizing to work with Healixa, Inc. – Broadcast: Bloomberg TV and NEWSMAX TV.
Cryptocurrency, Finxflo (FXF) CEO James Gillingham, provide the “New To The Street” TV viewers information about their “KYT” (Know Your Transaction). He explains how the “KYT” system works for trading and best price for crypto platforms - https://www.finxflo.com/ .
NEWSMAX TV- Broadcast- Sunday, April 25, 2021
The “New toTheStreet’s” TV, 1-hour show, Sunday, April 25, 2021 on NEWSMAX TV to feature PetProducts.com, an Al Simon, WEE WEE Pad inventor company, Pet Segment. Pet Products.com will be on regularly with tips and pet product news on “what’s” happening in the pet industry- Broadcast: NEWSMAX TV .
Also, on the 1-hour, “New To The Street’s” NEWSMAX TV broadcast, cryptocurrency Native Coin (N8V). N8V’s President Randy Williams discusses the goal of the Company to help the Native American tribes with commerce and bring out the invisibility of this sovereign cryptocurrency- Broadcast: NEWMAX TV .
Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of the central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL 1 , is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 2021 2 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-1800 3 , is a live replicating vaccine based on the horsebox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-801 3 , live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox – www.tonixpharma.com
1 TNX-102 SL is an investigational new drug and has not been approved for any indication.
2 Pending agreement from FDA on statistical analysis plan
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, SaaS licensing, and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green and Efixii platforms are the world's first end-to-end - from patient to regulator - medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, GCAC is focused on generating revenue from SaaS licensing its technology, and acquiring high-quality cannabis datasets that improve patient outcomes and become the world's largest cannabis efficacy data provider- https://cannappscorp.com
About Healixa Inc.
Healixa is a technology company with assets in both health tech and fintech. Healixa marries code and care to create exceptional experiences in health tech. The Company's people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges. Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics, and more.
About Finxflo (FXF)
Finxflo is a platform that focuses on the changing the cryptocurrency market through innovation. As the world’s first hybrid DeFi/CeFI liquidity and protocol aggregator, Finxflo brings a one-stop solution for all crypotcurrency trades and investors. Using only one account with KYC (Know Your Client), our users are able to utilize liquidity from 25+ various CeFi and DeFi platforms through a single user interface. Finxflo blends all the upsides of DeFi and CeFi ecosystems to produce the ultimate product - https://www.finxflo.com/
About Petproducts.com
PetProducts.com has been the leading global directory for all things pet. We are now giving consumers direct access to the products they need. We provide a one-stop shop for products, research, and reviews. PetProducts.com works diligently to serve pet lovers who deeply care about their animals - https://www.petproducts.com/
About NativeCoin (N8V)
NativeCoin is a digital currency running on the Ethereum blockchain network and is specially made for Native American Tribes and their businesses. This Native American Sovereign Cryptocurrency is made to be used by Tribal casinos and other enterprises in the United States and around the world - https://native-coin.com/ .
About FMW Media
FMW Media operates one of the longest-running U.S and International sponsored and Syndicated Nielsen Rated programming T.V. brands "New to the Street," and its blockchain show "Exploring The Block." Since 2009, these brands run biographical interview segment shows across major U.S. Television networks. The TV platforms reach over 540 million homes both in the US and international markets. FMW recently added Newsmax to its broadcasting platform with its first show broadcasted Sunday, December 27th. The NEWSMAX New to The Street show is syndicated on Sundays at 10 AM EST. FMW is also one of the nation's largest buyers of linear Television long and short form- https://www.newsmaxtv.com/Shows/New-to-the-Street
https://www.newtothestreet.com/
FMW Media Contact:
Bryan Johnson
+1 (631) 766-7462
Bryan@NewToTheStreet.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ec766ce9-a2a0-44c1-86ec-433d6a52892f
Primary Logo
News Provided by GlobeNewswire via QuoteMedia
SUPPLEMENTAL INFORMATION AND DISCLOSURE STATEMENT OF MATERIAL CORPORATE EVENT
FOR IMMEDIATE RELEASE – April 24, 2021
HEALIXA INC
(f/k/a Emerald Organic Products Inc.)
CUSIP: 29101T103
Trading Symbol: EMOR
OTC Pink SupplementalDisclosure
We at Healixa, Inc. (OTC: EMOR, f/k/a Emerald Organic Products Inc.) (“EMOR”) filed a lawsuit on April 20, 2021
against Matthew J. Wanderer and Carie Health, Inc. (f/k/a Carie Health, LLC and Epic Health, LLC (“CHI-E”) and certain
unnamed coconspirators listed as “John Doe Defendant(s)” (collectively the “Defendants”) in the Supreme Court of
the State of New York, County of Suffolk, as a result of a dispute involving a conditional merger agreement entered
into between EMOR and CHI-E on March 30, 2020 which EMOR terminated.
The lawsuit alleges multiple counts of fraud, breach of contract and conversion against the Defendants and seeks a
judicial confirmation that the merger was properly terminated before it closed or, in the alternative, that it should
be deemed a nullity due to procedural irregularities and fraudulent inducements that were revealed in the
continuing due diligence process.
While EMOR plans to vigorously enforce our rights, we cannot predict the outcome of any litigation matter.
Forward-looking Statements
Certain statements contained in this disclosure may constitute forward-looking statements. For example, forwardlooking statements are used when discussing our expected research and development programs, and more. These
forward-looking statements are based only on current expectations of management and are subject to significant
risks and uncertainties that could cause actual results to differ materially from those described in the forwardlooking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost,
and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory
approval or patent protection; and competition from other companies. Except as otherwise required by law,
Healixa Inc., (f/k/a Emerald Organic Products, Inc.), undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
/s/ Ian Parker, Chief Executive Officer
https://backend.otcmarkets.com/otcapi/company/financial-report/279748/content
$EMOR Pharmacy Business Plan Rollout
The Company has begun integrating 5 Star Pharmacy LLC into its digital healthcare ecosystem;
The Company is in its final stages of testing its Rx last mile logistics application;
Upon completion of testing this quarter the Company’s digital pharmacy application will be launched nationally in strategic regional locations in and in phases, beginning with select metropolitan areas.
Sweet...the more News coverage for $EMOR, the greater potential for current and potential investors!
$EMOR News on the pharmacy acquisition in Texas is getting extra coverage from Seeking Alpha as well:
https://seekingalpha.com/news/3674649-healixa-buys-5-star-pharmacy-llc-in-allen-texas?utm_source=advfn.com&utm_medium=referral
This is key to the success of $EMOR... especially cost-effective healthcare!
The Medical Advisory Committee will focus on health innovation and cost-effective short- and long-term care, clinically sound, ethical tech-enabled solutions.
Very good to see the latest news from EMOR which is directed at placing the company in an even stronger position to address the most pressing medical issues today and to best allow the company to respond to them.
Healixa Inc. to Establish Nationally Recognized Medical Advisory Committee
Holbrook, New York, April 15, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges is pleased to announce the formalization of a nationally recognized Medical Advisory Committee.
Company’s seasoned group of medical professionals announces they have been in stealth mode for several months while the organization continued its pursuit to formalize a Medical Advisory Committee comprised of physicians and health care professionals with considerable experience in nationally recognized healthcare organizations and academic institutions like CVS, Optum, Aon, Yale-New Haven Health, Rutgers University, University of Southern California, and many others.
Healixa’s Medical Advisory committee sparked the interest of visionary healthcare innovators and professionals who believed that care and code needed an ethical foundation upon which to build. Healixa’s Medical Advisory Committee was established to guide Healixa companies by representing the voices of physicians, healthcare professionals, and patients nationally.
“We will continue to partner with specialists in Emergency Medicine, Family Medicine, Internal Medicine, Public Health, Oncology, Health Administration, Cardiology, Nutrition, Mental Health, Dermatology and more,” said CEO, Ian Parker, “We recognize that the power of our combined efforts exceeds what we can accomplish individually, and we are accountable to each other as leaders, team members, and to our customers.”
The roles of each advisory member include serving as a conduit for input on key initiatives, leading clinical product development and process improvement, providing insights on scientific and medical innovations, and contributing as healthcare thought leaders and advocates for the communities and professionals for whom Healixa is focused on serving.
These soon to be announced inaugural committee members champion Healixa’s mission to humanize healthcare by providing life-changing, personalized, preventative, and action-driven care, while meeting the patient at every stage of their care journey.
Amidst ongoing reform in healthcare and the big tech healthcare movement, the need for physician collaboration and leadership is critical. The Medical Advisory Committee will focus on health innovation and cost-effective short- and long-term care, clinically sound, ethical tech-enabled solutions.
“The interest we have garnered from well known, globally recognized physicians and health care professionals to join the Committee speaks to the completeness of the Healixa Health Care Eco System. As care continues to redefine itself and evolve so will Healixa’s Board of Directors, management, and advisory team,” said Ian Parker, “We are humbled to be collaborating with the Justice League of Healthcare Leaders and Professionals making our possibilities indeed limitless.”
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
Looking forward to hearing more about this Advisory Committee!
These soon to be announced inaugural committee members champion Healixa’s mission to humanize healthcare by providing life-changing, personalized, preventative, and action-driven care, while meeting the patient at every stage of their care journey.
$EMOR
$EMOR In the NEWS as Healixa Inc. to Establish Nationally Recognized Medical Advisory Committee https://finance.yahoo.com/news/healixa-inc-establish-nationally-recognized-181600674.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
On a very RED day in the OTC Markets, $EMOR is green, up 10% and trading just below its 10-day average volume.
Very exciting news from $EMOR!
Emerald Organic Products Inc. (d/b/a Healixa Inc.) in Final Stages of Testing for its Proprietary Prescription Delivery Technology
$EMOR NEWS! Healixa Inc. Provides Pharmacy Business Progress Updates https://finance.yahoo.com/news/healixa-inc-provides-pharmacy-business-175200567.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
$EMOR trading at almost 4x its 10-day average volume...maybe the price will follow soon.
Interesting choice of words at the end there..
“Outside of the office, you'll find me being a dedicated "foodie" and chasing down the latest quirky bite or jumping on a flight to some unplanned destination with family or friends, says Altman. “I am elated to be on this journey with Healixa. Who knows, I’ve always dreamed of ringing that bell...the possibilities are limitless.”
$EMOR
$EMOR [CORRECTION] Healixa Inc. Appoints Kealy Altman as Vice President of Marketing
Press Release | 04/06/2021
Holbrook, New York, April 06, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, today announces that its Board of Directors (the “Board”) appointed Kealy Altman as Vice President of Marketing, effective immediately. This announcement closely follows the Company’s March 31, 2021 announcement regarding the appointment of McKenzie Gallagher to its Advisory Board, the Company’s March 8, 2021 announcement regarding the appointment of Rep. Denver Riggleman to its Advisory Board, and its March 11, 2021 announcement regarding the appointment of Jessica Múzquiz.
Altman is a native Floridian who graduated from Florida State University with a bachelor’s degree in marketing and merchandising. Whether at established corporations or nimble start-ups, she is passionate about creating order from chaos and thrives in a creative, fast-paced environment. Altman has developed and overseen multiple healthcare and telemedicine go-to-market initiatives and collaborations such as Walgreens, Cigna, BCBS, Bloomberg, LabCorp, MasterCard, Humana, Sutter Health Hospital System, IEHP, Aetna, IBM Watson, national trade shows, and many others.
“In my seven-ish years in the virtual healthcare industry, I have had the privilege to help build one of the industry's most successful telehealth companies. Starting with 5 employees, to over 500 employees, vendors galore, and countless partner channels. My team was instrumental in achieving two important tasks. Both which held value to investors and the market at large. One, was onboarding over 30+ million lives, the other, was driving member and patient engagement. A task which may seem relatively easy to most people, but to the novice, quite the contrary. Most people have little to no idea what is available within their health plan, let alone how to activate or use any of the services for which they pay. My job was to educate 300 million Americans, health insurance companies, pharmacy chains, lab chains, employer groups, hospital systems, urgent care centers, and venture capital groups to effectively understand the answers to key market questions. What was telemedicine? Why was it an essential product? How easy was it to access? and most importantly, why everyone needed it. I led record-setting patient registrations and virtual doctor visits including implementing a digital assessment management system, which increased revenues and contributed to the overall company valuation at MDLIVE”, says Altman.
The company recently announced the name change to Healixa and rebranding initiatives. “Altan is filling a critical role in our organization. We’ve had several marketing vendors, none of which understood our scope or our omnichannel approach. She embraced our culture, sprung into action, and moved mountains to begin our rebranding initiatives. As we enter a market that is saturated with names, concepts, start -ups and niche domain names, having a fresh approach from a seasoned leader and brand marketer is key”, says Ian Parker CEO of Healixa Inc.
“Outside of the office, you'll find me being a dedicated "foodie" and chasing down the latest quirky bite or jumping on a flight to some unplanned destination with family or friends, says Altman. “I am elated to be on this journey with Healixa. Who knows, I’ve always dreamed of ringing that bell...the possibilities are limitless.”
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
$EMOR will leverage this expertise to grow
“In my seven-ish years in the virtual healthcare industry, I have had the privilege to help build one of the industry's most successful telehealth companies. Starting with 5 employees, to over 500 employees, vendors galore, and countless partner channels."
$EMOR Healixa Inc. Appoints Kealy Altman as Vice President of Marketing
Press Release | 04/06/2021
Holbrook, New York, April 06, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, today announces that its Board of Directors (the “Board”) appointed Kealy Altman as Vice President of Marketing, effective immediately. This announcement closely follows the Company’s March 31, 2021 announcement regarding the appointment of McKenzie Gallagher to its Advisory Board, the Company’s March 8, 2021 announcement regarding the appointment of Rep. Denver Riggleman to its Advisory Board, and its March 11, 2021 announcement regarding the appointment of Jessica Múzquiz.
Altman has developed and overseen multiple healthcare and telemedicine go-to-market initiatives with MDLIVE and collaborations such as Walgreens, Cigna, BCBS, Bloomberg, LabCorp, MasterCard, Humana, Sutter Health Hospital System, IEHP, Aetna, IBM Watson, national trade shows, and many others. A native Floridian, Altman graduated from Florida State University with a bachelor’s degree in marketing and merchandising. Whether at established corporations or nimble start-ups, she is passionate about creating order from chaos and thrives in a creative, fast-paced environment.
“Following the company's recently announced name change to Healixa and refocusing initiatives, Altman is filling a critical role in our organization. She embraces our culture, and has begun moving mountains for our rebranding initiatives. Her fresh approach as a seasoned leader and brand marketer is key”, commented Ian Parker CEO of Healixa Inc.
“In my seven-ish years in the virtual healthcare industry, I have had the privilege to help build one of the industry's most successful telehealth companies. Starting with 5 employees, to over 500 employees, vendors galore, and countless partner channels. My team was instrumental in achieving two important tasks. Both which held value to investors and the market at large. One, was onboarding over 30+ million lives, the other, was driving member and patient engagement. A task which may seem relatively easy to most people, but to the novice, quite the contrary. Most people have little to no idea what is available within their health plan, let alone how to activate or use any of the services for which they pay. My job was to educate 300 million Americans, health insurance companies, pharmacy chains, lab chains, employer groups, hospital systems, urgent care centers, and venture capital groups to effectively understand the answers to key market questions. What was telemedicine? Why was it an essential product? How easy was it to access? and most importantly, why everyone needed it. I led record-setting patient registrations and virtual doctor visits including implementing a digital assessment management system, which increased revenues and contributed to the overall company valuation at MDLIVE”, said Altman. “I am elated to be on this journey with Healixa. Who knows, I’ve always dreamed of ringing that bell...the possibilities are limitless.”
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
$EMOR is trading over 4x its 10-day average volume...up almost 15%!
This is a long term hold. Patience will pay here $EMOR$
CVS Pharmacy has a similar structure... pharmacy with added features like a wellness center. It's very cool.
$EMOR is making a great move!
ME too. This pharmacy strategy sounds like it will work.
$EMOR
I like the idea of a one stop pharmacy with added features. It negates the need for a dedicated doctor located in one location. $EMOR
5 Star is a multifaceted pharmacy where pharmacists store, prepare, and dispense medicinal preparations and/or prescriptions for a local patient population counsel patients and caregivers administer vaccinations, and provide other professional services associated with pharmaceutical care including health screenings, consultative services with other health care providers, collaborative practice, disease state management, patient monitoring, adherence education, and educational classes.
Very strong credentials for the $EMOR board...
“I’m excited to be joining the Company during its rapid entry into the healthtech sector,” commented McKenzie Gallagher. “I look forward to applying my professional and entrepreneurial experience in leading growth at an organization committed to serving the healthcare needs of customers and communities in such an innovative way.”
$EMOR NEWS! Healixa Inc. Appoints McKenzie Gallagher to Advisory Board https://finance.yahoo.com/news/healixa-inc-appoints-mckenzie-gallagher-130000061.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
"The acquisition of 5 Star Pharmacy was the perfect choice for Healixa's growing healthcare portfolio, and acts as the first phase of the Company’s national pharmacy business plan rollout,” commented Ian Parker, CEO of Healixa. “As Silicon Valley's healthtech and fintech giants continue to expand their footprint to the Dallas metro area - so do we. Healixa's strategic plan to make Dallas, Texas the central command headquarters for the Company’s pharmacy operations is quickly coming to fruition."
$EMOR
$EMOR Emerald Organic Products Inc. (d/b/a Healixa Inc.) announces execution of its Phase I national pharmacy business plan rollout. https://finance.yahoo.com/news/healixa-inc-acquires-5-star-151600447.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
The latest EMOR news on the pharmacy acquisition in Texas is getting extra coverage from Seeking Alpha today. Nice.
Click here:
https://seekingalpha.com/news/3674649-healixa-buys-5-star-pharmacy-llc-in-allen-texas?utm_source=advfn.com&utm_medium=referral
$EMOR NEWS! Healixa Inc. Acquires 5 Star Pharmacy LLC in Allen, Texas https://finance.yahoo.com/news/healixa-inc-acquires-5-star-151600447.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Healixa Inc. Acquires 5 Star Pharmacy LLC in Allen, Texas
Holbrook, New York, March 19, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, today announces the purchase of 5 Star Pharmacy LLC (“5 Star”), a community retail pharmacy, in Allen, Texas (“Allen”).
5 Star is a multifaceted pharmacy where pharmacists store, prepare, and dispense medicinal preparations and/or prescriptions for a local patient population counsel patients and caregivers administer vaccinations, and provide other professional services associated with pharmaceutical care including health screenings, consultative services with other health care providers, collaborative practice, disease state management, patient monitoring, adherence education, and educational classes.
"The acquisition of 5 Star Pharmacy was the perfect choice for Healixa's growing healthcare portfolio, and acts as the first phase of the Company’s national pharmacy business plan rollout,” commented Ian Parker, CEO of Healixa. “As Silicon Valley's healthtech and fintech giants continue to expand their footprint to the Dallas metro area - so do we. Healixa's strategic plan to make Dallas, Texas the central command headquarters for the Company’s pharmacy operations is quickly coming to fruition."
The city of Allen, Texas is a rapidly-growing economic center, and has served as the corporate headquarters for numerous companies including the Credit Union of Texas, and many others. According to the Allen Economic Development Corporation, Allen’s population reached 108,706 residents in 2020, more than doubling from just over 45,000 in the year 2000. Allen’s population is projected to reach 123,018 by 2025. Allen is located in Collin County, one of the fastest-growing counties in the Dallas-Fort Worth metropolitan area. Collin County’s population reached 1,092,478 in 2020, and is estimated to reach 1,255,347 in 2025. Allen’s diverse population contributes to its unified community spirit and economic growth potential.
Allen is also home to the Watters Creek Convention Center, with an estimated 79,000 square feet of meetings and event space. In addition, Allen also has a multi-purpose arena, the 7,500-seat Allen Event Center, which is owned and operated by the City of Allen.
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
Healixa to Present at the Emerging Growth Conference on March 17, 2021
Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
Holbrook, New York, March 15, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, is pleased to announce that it has been invited to present at the Emerging Growth Conference on March 17, 2021.
The third Emerging Growth Conference is set to take place on March 17, 2021. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Healixa’s Chief Executive Officer, Ian Parker in real time.
Mr. Parker will perform a presentation and will subsequently open the floor for questions. Please ask your questions during the event and Mr. Parker will do his best to get through all of them in the allotted amount of time.
Healixa (OTC Pink: EMOR) will be presenting at 11:45 AM Eastern time for 30 minutes.
Please register here to ensure you are able to attend the conference and receive any updates that are released.
Here is the unique link: https://register.gotowebinar.com/register/6904637667304920590?source=EMOR
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and we will also release a link to that after the event.
About Emerald Organic Products
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
About the Emerging Growth Conference
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. The Emerging Growth Conference was launched to showcase niche companies in specific sectors. It identifies companies with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner. The audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone. Provided above is the current Emerging Growth Conference schedule for featured presentations. Each company’s presentations will be delivered by their executive management team. The Emerging Growth Conference focus and coverage includes a wide range of growth sectors and timely market themes, including, augmented reality, artificial intelligence, scientific, medical instruments and therapeutics, biotechnologies, cannabis, food & beverage, energy and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., (f.k.a. Emerald Organic Products, Inc.), undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
Source: Emerald Organic Products Inc.
$EMOR NEWS: The 3rd Emerging Growth Conference is here. 9:30 AM Start Time. Register now. https://ih.advfn.com/stock-market/USOTC/emerald-organic-products-pk-EMOR/stock-news/84602276/the-3rd-emerging-growth-conference-is-here-9-30-a
$EMOR Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. https://finance.yahoo.com/news/healixa-present-emerging-growth-conference-223000046.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Good to see EMOR will be in the spotlight at the Emerging Growth Conference this week. Presentation set for 11:45 AM on the 17th.
Emerging Growth Conference 3 Announced for March 17, Niche Companies in Tech, Pharma, Cannabis, Solar and more in Attendance
MIAMI, March 16, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies announces the Schedule of the 3rd Emerging Growth Conference.
EmergingGrowth.com is proud to present and welcome you to the 3rd Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.
Register for the conference here.
The schedule for March 17th from 9:30 AM until 3:30 PM is as follows:
(All times are eastern time)
We may see some schedule changes on Wednesday. To stay current on the schedule, please follow us on Twitter: https://twitter.com/EmergingGrowthC
9:30 – 10:00 Verb Technology Corp. (NASDAQ: VERB)
Rory Cutaia, CEO
10:00 – 10:30 Blockchain2 Corp. (OTCQB: BIDCF)
Tony Caputo, CEO Presenting
10:30 - 11:15 Treasure Investments dba Foundry Michelangelo
Mark Russo, Founder / Chairman presenting
For Treasure Investments, Click here.
11:15 – 11:45 CordovaCann Corp. (OTCQB: LVRLF)
Taz Turner, CEO presenting
11:45 – 12:15 Healixa, Inc. (OTC Pink: EMOR)
Ian Parker, CEO presenting
12:30 - 1:15 Benchmark Metals, Inc. (OTCQX: BNCHF)
James Greig, President presenting
1:15 - 2:00 Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)
Seth Lederman, CEO, President
2:00 - 2:30 Global Cannabis Applications Corp. (OTC Pink: FUAPF)
Brad Moore, CEO presenting
2:30 – 3:00 West Mining Corp. (OTC Pink: WESMF)
Nick Houghton, CEO presenting
3:00 - 3:30 Green Stream Holdings, Inc. (OTC Pink: GSFI)
Alan Stone presenting
All interested in attending should visit the following link to register. You will then receive an email containing the link and time to sign into the conference.
Register for the conference here.
We may see some schedule changes on Wednesday. To stay current on the schedule, please follow us on Twitter: https://twitter.com/EmergingGrowthC
These exciting virtual conferences are like attending an “in person” event, you can sign in and out as often as you like.
About EmergingGrowth.com
Founded in 2009, Emerging Growth.com quickly became a leading independent small cap media portal. Over the years, it has developed an extensive history of providing unparalleled content, in identifying emerging growth companies and markets that can be overlooked by the investment community.
The next step in its evolution is the Emerging Growth Conference.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in an effective and time efficient manner.
The Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.
Our audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
Thanks for participating and make sure you are on our VIP list so you are informed immediately as we announce updates to our upcoming Conferences.
Get on the list here – Emerging Growth Conference VIP List
All Conferences are first announced on Twitter – Follow us on Twitter
All Conference replays emerge on our YouTube Channel – Subscribe to our YouTube Channel
All sessions will be conducted through video webcasts and will take place in the Eastern time zone. Provided above is the current Emerging Growth Conference schedule for featured presentations. Each company’s presentations will be delivered by their executive management team. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients. Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future. In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with the offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.
If you believe your company, product or service is at the cusp of going mainstream, or you have an idea for an “Emerging Growth” company that might fit our model, contact us here.
Thank you for your interest in our conference, and we look forward to your participation in future conferences.
Contact:
Emerging Growth
Phone: 1-305-330-1985
Email: Conference@EmergingGrowth.com
$EMOR NEWS! Emerging Growth Conference 3 Announced for March 17, Niche Companies in Tech, Pharma, Cannabis, Solar and more in Attendance https://finance.yahoo.com/news/emerging-growth-conference-3-announced-110000957.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the "Company", "EMOR", "Healixa") is a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges
$EMOR dba/Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company's people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
$EMOR Emerald Organic Products Inc. (d/b/a Healixa Inc.) Bolsters Pharmacy Leadership with Recent Appointment; Healixa Inc. Appoints Jessica Muzquiz to Advisory Board https://www.marketwatch.com/press-release/healixa-inc-appoints-jessica-muzquiz-to-advisory-board-2021-03-11?reflink=mw_share_twitter
Healixa Inc. Appoints Jessica Muzquiz to Advisory Board
Holbrook, New York, March 11, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, today announces that its Board of Directors (the “Board”) appointed Jessica Muzquiz to its Advisory Board, effective immediately. This announcement closely follows the Company’s March 8, 2021 announcement regarding the appointment of Rep. Denver Riggleman to its Advisory Board.
Muzquiz was a natural choice to lead the charge in advising the Company’s pharmacy acquisitions, pharmacy operations, and solutions development. Her extensive leadership experience with Fortune 500 companies as well as her accomplished career in the United States military is best-in-class. Through working with Frazier Healthcare to her instrumental role within the BriovaRx, Catamaran acquisition by Optum for 12.8 billion, her contribution to the healthcare, health tech, and logistic sectors are both unique and noteworthy.
Muzquiz served as Vice President - Human Capital Partner at UnitedHealth Group Inc., following the acquisition of Catamaran Corp. by OptumRx, a division of UnitedHealth Group. Previously, Muzquiz served in executive leadership roles at Supreme Group and the United States Postal Service. Muzquiz began her career in the United States Army, where she was decorated two times with the Army Achievement Medal, and decorated three times with the Army Commendation Medal. Muzquiz holds her Bachelor of Science and MBA from Waynesburg University.
"Jessica's background in complex and regulated logistics fascinated me from the start. She grew Supreme Group’s workforce from 5 to over 2,000 employees in six months and then duplicated that growth management a few years later in the specialty pharmacy space with Catamaran, OptumRx, and beyond. Her forward-thinking mind and ability to execute at large scale are commendable. On behalf of the entire Board, we are eager to realize Jessica’s proven organizational impact. We are excited to see what our futures hold together," says CEO Ian Parker.
“I’m excited to be joining the Company during a period of tremendous growth,” commented Jessica Muzquiz. “I look forward to applying my skills and experience in leading transformation at an organization committed to serving the needs of their customers in such an innovative way.”
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
Healixa Inc. Appoints Rep. Denver Riggleman to Advisory Board
Press Release | 03/11/2021
[Re-Release]
Former United States Representative Denver Riggleman joins the Advisory Board of Emerald Organic Products Inc. (d/b/a Healixa Inc.)
Holbrook, New York, March 2, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the "Company", "EMOR", "Healixa"), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, today announces that its Board of Directors (the "Board") appointed Former U.S. Representative Denver Riggleman to its Advisory Board. Rep. Riggleman served as the United States Representative for Virginia's 5th congressional district, and is an Air Force veteran and national security expert. Rep. Riggleman is also a successful businessman and co-owner of Silverback Distillery.
"Rep. Riggleman has thoroughly impressed the Board with both his business acumen and his deep understanding of our technologies," said Ian Parker, CEO of Healixa. "His connectivity and experience will be invaluable as we accelerate our global expansion and continue to evolve our solutions. We are excited to have Rep. Reiggleman on our Advisory Board and look forward to working closely with him."
Rep. Riggleman added, "Health and financial institutions are continually evolving with new technologies. Healixa is one of the few companies I have seen that has effectively combined engagement, real-time transactions, and ethical engineering. I am excited to be a part of this board and help move these technologies into the future."
Healixa is actively building a robust Advisory Board which will utilize its collective knowledge and expertise to provide guidance and direction to the Companys executive team as it continues to grow and expand. Healixa highly values the broad range of experience that Rep. Riggleman brings to the Advisory Board, which include government, defense, national security and executive management.
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under the symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Companys people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
$EMOR Emerald Organic Products Inc. Announces Corporate Name Change to Healixa, Solidifying a Position at the Tech Table
Press Release | 02/24/2021
Holbrook, New York, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (d/b/a Healixa Inc.) (OTC: EMOR) (the “Company”, "EMOR", “Healixa”), a people-first digital organization that humanizes care by deploying simplified solutions for complex global challenges, today announces that the Company has embarked on an extensive rebranding effort in response to accelerated Company growth and a refined corporate vision. The adoption of the Healixa name reflects the Company’s emphasis on developing “healing technology” solutions intended to meet the needs of the Company's diverse customer base.
Over the past year, EMOR has cemented its status as an emerging market leader in healthtech. Fueled by its recent fintech joint venture with Swys Inc, the name Healixa represents EMOR’s commitment to healing the fragmented user experience by blending the various elements of the digital assets.
“As we head toward more significant revenues, it became important to fortify our efforts with a name that was inclusive of all of our digital assets and not just a piece of our overall ecosystem. Healixa represents the expanded vision of the Company to capitalize on our unique combination of talent and technology,” said Ian Parker, CEO of Healixa. “This new branding and evolving positioning perfectly illustrates our growth strategy.”
Healixa employs ethical engineering practices to marry code and care, creating exceptional user experiences. Combining specific elements of the company's healthtech and fintech assets has been Healixa's main focus and an important accomplishment. With both industries quickly expanding, EMOR is uniquely positioned to capitalize on the convergence of two important tech segments which will present significant opportunities for Healixa's current and future products within the marketplace.
About Emerald Organic Products Inc.
Emerald Organic Products Inc. has recently changed its name to Healixa Inc. in the State of Nevada and continues to trade under symbol OTC: EMOR. Filings have been made to reflect the name change on the OTC ticker board.
About Healixa Inc.
Healixa is a technology company with assets in both healthtech and fintech. Healixa marries code and care to create exceptional experiences in healthtech. The Company’s people-first approach is designed to humanize care via purpose-driven ethical engineering practices, deploying simple solutions for complex global challenges.
Healixa offers value-based tech solutions to enterprise partner channels across a broad range of industries including employer benefits, travel, pharma, logistics and more.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs, and more. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. Except as otherwise required by law, Healixa Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Kirin M. Smith
PCG Advisory, Inc.
1-646-823-8656
ksmith@pcgadvisory.com
$EMOR Emerald Organic Products Signs Term Sheet to Form Health Benefits Joint Venture with Health Services Hub
Press Release | 08/06/2020
Holbrook, New York, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Emerald Organic Products Inc. (OTC: EMOR) (the “Company”, "Emerald", or "Emerald Organic Products"), an integrated health technology company, is pleased to announce that, further to its August 3, 2020 press release regarding the Company’s vision, key business-building strategies and new developments, it has signed a Term Sheet (the “Term Sheet”) to form a Joint Venture with Health Services Hub (the “Joint Venture”), an established ancillary benefits administrator.
Health Services Hub is one of the leading care benefits management platforms. Health Services Hub offers employers, TPAs, alumni, affinity groups and consumers a suite of centralized tools for easy access to their care benefits; on-demand expert health advice, health and wellness assessment programs and more, all through a fully-integrated, user-centric interface.
By co-bundling product and benefit offerings, the Company’s highly scalable infrastructure will provide same-day last mile prescription and OTC drug delivery services to the Health Services Hub product suite and allow for cross-promotion and cross-marketing of additional health and wellness benefits.
"This is a unique opportunity to combine two innovators in the healthtech industry who seek to defragment the care continuum, thereby driving patient value and enabling consumers to take action on their own health care decisions," said Ian Parker, Chief Executive Officer of Emerald Organic Products. "Ours and Health Services Hub’s offerings are being integrated harmoniously and, together, will provide greater end-user experiences, improving benefit packages for customers and employers alike."
Health Services Hub currently has over 1,500,000 lives on the platform from various groups.
This Joint Venture brings a strong, highly accretive distribution network, and a sophisticated patient enrollment portal that enables efficient and modernized benefits administration, strengthening the Company’s position in the fragmented health and wellness benefits market.
"Partnering with Health Services Hub helps us to build upon our goal of offering a broad suite of solutions to our pharmacy and telehealth partners, all with a common goal of providing patients with better access to consistent, high quality care at a fair price," added Parker.
Chris Barr, Founder of Health Services Hub, commented, "For years, Health Services Hub has focused on making employer benefits simpler to access and easier to understand. Marrying both company's innovative engagement strategies, technology and service offerings will deliver on our shared goal of providing the highest quality and value benefits. Our suite of benefits coupled with our robust user lifetime value cements our position as leaders in the healthtech market."
About Emerald Organic Products, Inc.
Soon to be known as Carie Health, Inc., Emerald Organic Products' objective is to build, as well as acquire, technology that touches people at the most important points of their lives. Carie, through its subsidiaries, uniquely combines virtual care capabilities with digital pharmacy and prescription delivery offerings in a streamline ecosystem to democratize and defragment patient access to products and services within the healthcare continuum.
For more information, please visit https://www.emerald-organic.com/, https://www.carie.com/, https://www.carierx.com, and https://carieglobal.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs and more. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Carie Health, Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
$EMOR Emerald Organic Products CEO Issues Letter to Shareholders Commenting on the Company’s Name Change, Vision, and Strategic Developments
Press Release | 08/03/2020
Holbrook, New York, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Ian Parker, Chief Executive Officer of Emerald Organic Products Inc. (OTC: EMOR) (the “Company”, "Emerald Organic", or "Emerald Organic Products"), a diversified health sciences company, today issued a letter to shareholders on the Company’s website commenting on the Company’s vision, key business-building strategies and new developments serving to position itself as one of the world’s leading healthcare technology companies. The letter states, in summary:
On March 27th, 2020, Emerald Organic Products announced that it signed a Plan of Merger Agreement to acquire a 51% controlling interest in Bonsa Health, a digital pharmacy platform enabling same-day delivery of prescriptions anywhere in the United States. On March 31st, 2020, Emerald Organic Products announced that it entered into a definitive agreement to acquire 100% of Carie Health, a leading telehealth and virtual care technology and service solutions company.
To reflect its unification and integration of Bonsa Health and Carie Health, as well as its positioning as a disruptive healthcare technology company that defragments and democratizes health and wellness through its end-to-end ecosystem, the Company is in the final stages of changing its name to Carie Health, Inc. (“Carie”). We expect our legacy consumer packaged good (“CPG”) operations to play a key role in delivering additional value to the end-users in our ecosystem.
Carie’s objective is to build, as well as acquire, technology that touches people at the most important points of their lives. This current health crisis has made the Company acutely aware that accessibility and affordability of quality healthcare and health products is not a constant in this country. Democratizing health and wellness through modernization and innovation is at the core of that objective. We believe our combination of virtual care capabilities and digital pharmacy and prescription delivery together uniquely positioned Carie to meet this demand.
Carie has entered into a Letter of Intent to acquire a network of strategically positioned pharmacies to enhance Carie’s prescription drug delivery capabilities while further defragmenting the healthcare vertical. Furthermore, Carie’s strategic acquisition target currently generates annual revenues greater than $120 million, thereby enhancing the Company’s financial position.
Carie is completely committed to continuing to build the most complete healthcare ecosystem to encompass and optimize the entire chain of care, extend customer and patient engagement, and increase immediate and long-term value to every participant within the ecosystem.
About Carie Health, Inc.
Based in Holbrook, Carie is a diversified health sciences and technology company focused on providing consumers with one of the most robust health and wellness offerings available today. Through its subsidiaries, Emerald is dedicated to both bringing to market, and democratizing access to healthcare services and wellness products. For more information, please visit https://www.emerald-organic.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs and more. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection; and competition from other companies. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Carie Health, Inc., f.k.a. Emerald Organic Products, Inc., undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
$EMOR Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S
Press Release | 07/16/2020
REHOVOT, Israel, NEW YORK and Shanghai, July 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that its partner supplier 3D Medicines Corporation (3D Med) has received authorization from the Brazilian Health Surveillance Agency (ANVISA) to distribute its COVID-19 qPCR test kits and ANDis extraction systems.
On July 10, 2020, Todos Medical announced the expansion of its agreement with 3D Med to include COVID-19 testing product distribution rights in multiple international markets including Brazil, as well as in the U.S.
For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com.
For testing and PPE inquiries, please email sales@todosmedical.com.
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the third quarter of 2020.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements with multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos, via its wholly-owned subsidiary Corona Diagnostics LLC, has formed strategic partnerships with Meridian Health, Moto-Para Foundation, Emerald Organic Products, Inc.’s (OTC: EMOR) subsidiaries Carie.com and Bonsa Health to help deploy COVID-19 testing in the United States.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Investor and Corporate
$EMOR Nationwide On-Site Coronavirus Testing Program
Press Release | 07/06/2020
REHOVOT, ISRAEL, July 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ? Meridian HSN has partnered with Moto-Para and Todos Medical (OTCQB: TOMDF) to provide a complete turnkey solution for on-site COVID testing.
Our Medical staff is directed by Moto-Para, a non-profit organization providing well trained retired service veterans from all branches of the military including Navy Seals, Force Recon Marines, Army Rangers, Green Beret encompassing site operations, physicians, paramedics, and nurses. Our teams enable us to set up testing sites anywhere in the US for any length of service.
Our Test Kits are provided by Todos Medical, an internationally recognized leader and public traded Israel company with NYC corporate offices and US-based labs supplying tests and robotic equipment.
We consult and provide every step needed surrounding safe and secure PCR and Rapid testing including telemedicine with medical personnel to write scripts. The number of tests that can be done is based on the need. Our resources are extensive and provide CLIA high complexity labs, testing sites, CLIA certified staff, and full documentation.
Cost of testing is determined by volume and sources of funding. The organization asking for testing must demonstrate the funding available to pay for testing. The key elements are not just testing, but data collection, telemedicine, and results delivered in a rapid manner within 24 to 48 hours.
We supply all Personal Protective Equipment necessary to protect both the testers and the people being tested. We can supply a full line of PPE for ongoing use for organizations including ventilators, scanners, thermometers, masks, gloves, gowns, and shields at below market prices.
Key Points:
Antibody and RT-PCR (molecular) tests performed on-site with rapid turnaround.
Meridian and Todos provide a turnkey solution that includes physician supervision (telemedicine and/or on-site physician), mobile, High-complexity CLIA-certified laboratory, all clinical staffing, equipment, supplies, and site coordination.
The evaluation and testing can take place in any type of facility, parking lot, a mobile site, or some combination thereof.
The typical single-unit setup can perform in excess of 1,000 tests per day. We can provide services anywhere in the US.
Pricing based on size of testing group and location
We provide a full range of PPE both for the on-site testing and long-term needs.
Meridian Health Services Network 1.800.994.1143 www.Meridianhsn.com
About the SARS-CoV-2 Coronavirus (COVID-19)
Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is the disease caused by SARS-CoV-2.
About Moto-Para Foundation
MOTO+PARA™ delivers elite, global disaster ground-zero and last-mile logistics and mobility response employing highly trained Veteran Special Operations Forces Operators and Specialists as first response teams for urgent, complex, and prolonged emergencies using advanced rapid response apparatus delivered by air, land, and sea. As an asset-based NGO, we are always ready to serve with personnel, equipment, vehicles, aircraft, and ships anywhere in the world. http://www.motopara.org/
About Meridian Health Services Network
Since 2000 Meridian HSN has been assisting Fortune 1000 businesses, cities, schools and hospitals in managing and lowering health, benefits, and risk management costs through our network of services. Meridian serves thousands of patients daily through our Accountable Care Organization approach of assembling the nation’s leading providers into one resource led by our healthcare funding analysis. Our nationally recognized network is made up of health care providers, PBM management, PCP partners, telemedicine, as well as health and MSK assessment teams. Meridian clients average 10-20% savings on health and risk management costs compared to average industry costs. Meridian benefits average a 98% employee approval rating. Our clients and partners include National and State Council of Self Insurers, PRIMA, NAHU members, Gen7 Solutions and the American Red Cross. Our core association partners include national hotel chains, aviation, lumber, beverage providers, cities, state, universities, hospital networks, merchandising, power companies, casinos, consulting, and health underwriters. www.meridianhsn.com
About Todos Medical Ltd.
Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.
Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.
Todos recently entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements with multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed Corona Diagnostics, LLC, a strategic collaboration with Emerald Organic Products, Inc. (OTC: EMOR), to support telemedicine and virtual pharmacy aspects of the commercialization of its COVID-19 return to work testing programs in the US. www.todoscovid19.com
For more information, please visit https://www.todosmedical.com/
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Investor and Corporate Contact:
Kim Sutton Golodetz
LHA Investor Relations
Senior Vice President
(212) 838-3777
kgolodetz@lhai.com
Corporate Contact:
Daniel Hirsch
Todos Medical
(347) 699-0029
Dan.h@todosmedical.com
$EMOR Emerald Organic Products Launches Emerald Shield™ Division Alongside Nationwide Reopening and ‘Second Wave’ of Coronavirus
Press Release | 06/18/2020
Holbrook, New York, June 18, 2020 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. (OTC: EMOR) (the “Company”, "Emerald Organic", or "Emerald Organic Products"), a diversified health sciences company, is pleased to announce the launch of Emerald Shield™, an all-encompassing solution developed to facilitate necessary initiatives in a safety-conscious post-COVID-19 world. With a mission to support communities, companies, and municipalities across the United States, Emerald Shield’s key focus areas are its technologically-driven public safety solutions, and transformative health and wellness platforms.
As communities reopen, businesses and government agencies are actively seeking effective ways to keep the state safe by working with companies like Emerald Shield who specialize in sanitizing solutions.
“We have seen overwhelming interest from all industry sectors countrywide,” commented Ken Greenberg, Executive Vice President. “Restaurants, retailers and schools are just some of the businesses knocking on our door. People are eager for life to resume, yet many are still anxious. We believe what we offer can help restore community confidence in a visible, viable and responsible way.”
Emerald Shield’s Sanitizing Clean Booths provide a combination of the latest in technology and safety standards to bring businesses a cost-effective solution to protect both customers and staff. Placed at entrances, an automated infrared monitor first checks body temperature. Super-fine misters then lightly spray individuals in ?just a few seconds with an atomized solution containing Hypochlorous acid (“HOCl”), a time-tested, Environmental Protection Agency (“EPA”) approved ingredient for use in antimicrobial formulations such as food-contact surface sanitizing solutions. Furthermore, Hypochlorous acid is included in the May 2020 Interim guidance directive from the World Health Organization (“WHO”) titled “Cleaning and disinfection of environmental surfaces in the context of COVID-19.”
“HOCl has long been used in a wide variety of food and beverage processing as well as medical applications, leaving no sticky residue whatsoever,” added Michael Berg, Chief Development Officer of Emerald Organic Products.
Greenberg notes, "Multiple layers of protection are required to fight coronavirus; different methods need to work in tandem, synergistically. In addition to Sanitizing Clean Booths, Emerald Shield offers a wide variety of solutions and services to help businesses and communities reopen safely.”
Those interested in learning more about Emerald Shield are invited to visit www.emeraldshield.com.
About Emerald Organic Products, Inc.
Based in Holbrook, Emerald Organic Products, Inc. (OTC: EMOR), is a diversified health sciences and technology company focused on providing consumers with one of the most robust health and wellness offerings available today. Through its subsidiaries, Emerald is dedicated to both bringing to market, and improving access to, holistic and FDA-regulated products and services. Emerald offers high-quality dietary supplements from its flagship brands, Pura Vida Vitamins™, NxGen™, and Zenavita™. In addition, Emerald has acquired significant technology platforms in Bonsa Health and Carie Health Inc which will provide healthcare professionals and patients alike with a full suite of solutions to transform healthcare through the lenses of convenience and mobility. In Q4 2019, Emerald Organic Products established Emerald Organic Life Sciences, LLC. to develop biopharmaceutical assets licensed from Amarantus Bioscience Holdings, Inc. (OTC: AMBS). Emerald recently formed a collaboration with Todos Medical USA, Inc (OTC: TOMDF) for the purpose of providing technology solutions for Todos’s coronavirus (COVID-19) testing regime. For more information, please visit https://www.emerald-organic.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected research and development programs and more. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including but not limited to the risks and uncertainties related to the progress, timing, cost, and results of Partnerships and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; and competition from other companies. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Emerald Organic Products, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
124
|
Created
|
10/22/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |